Tilaknagar Industries Q1 Review - Earnings Beat Led By Strong Margins In A Challenging Environment: Systematix

The company is also exploring newer categories in the alcobev space to open up new growth avenues, adds the brokerage.

Tilaknagar Industries Ltd. (Source: Company)

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Systematix Research Report

Tilaknagar Industries Ltd.'s revenue growth was in line with our expectations while operating performance was above expected. Topline growth stood at 3% YoY with revenue of Rs 3.13 billion. Volume growth stood at 0.9% YoY to 2.54 million cases.

Net sales realisation grew 0.2% YoY to Rs 1,252 per case. The slowdown in growth was led by industry-wide disruption due to elections and thus the higher number of dry days.

The Southern states which contribute 85% to company’s volumes also witnessed a degrowth of 0.1%. Gross margin declined 75 bps to 49.6% due to inflationary pressure in ENA. However, Ebitda margin expanded 341 bps to 16% driven by cost optimisation initiatives and increase in share of premium products.

This also included a subsidy received from the State Government of Maharashtra of Rs 56 mn. Adjusted for the subsidy the Ebitda margin stood at 14.5%, still a margin expansion of 189 bps YoY. PAT witnessed strong growth of 55.7% to Rs 401 million majorly led by significant reduction in finance cost (-30.8% YoY). Company paid debt of Rs 223 million during Q1 FY25. The gross debt now stands at Rs 970 million while net debt at Rs 430 million.

Going forward, company expects volumes to grow in mid double digits and revenue growth to be ~300 bps higher over volume growth.

Click on the attachment to read the full report:

Systematix Tilaknagar Industries Q1 FY25 Results Review.pdf
Read Document

Also Read: Orchid Pharma Q1 Results Review - Revenue Growth Outperforms Expectations, Margins Come In Weaker: Systematix

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

lock-gif
To continue reading this story
Subscribe to unlock & enjoy all
Members-only benefits
Still Not convinced ?  Know More
Watch LIVE TV , Get Stock Market Updates, Top Business , IPO and Latest News on NDTV Profit.
GET REGULAR UPDATES